Enleofen Bio
Business Services · 1-10 Employees
View Company Info for Free
Overview
Website
www.enleofen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Enleofen Bio
Enleofen is a biotechnology company focused on developing innovative anti-fibrotic therapies, particularly targeting the IL-11 pathway, which plays a crucial role in fibrogenesis and inflammation in various diseases. The company utilizes a patient-based discovery platform and emphasizes therapeutic development grounded in relevant biology, ensuring efficacy and safety through extensive studies. Enleofen aims to transform the treatment of fibro-inflammatory diseases with its first-in-class therapeutics. Its intended clients include healthcare providers and patients affected by fibrotic diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Enleofen Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Enleofen Bio had a recent Job posting/layoffs
Earning: See what the market has to say on Enleofen Bio recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Enleofen Bio
Funding: Get notified immidiatlly once Enleofen Bio has new funding data
Website visits: Recent activity has been detected on your website
Check if Enleofen Bio has recently received funding, and reach out quickly before it becomes old news!
Enleofen Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Enleofen Bio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Enleofen Bio is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Enleofen Bio as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Enleofen Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Enleofen Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Enleofen Bio.
Enleofen Bio Tech Stack
A closer look at the technologies used by Enleofen Bio
Enleofen Bio News & Media
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
INGELHEIM AM RHEIN, Germany & SINGAPORE--(BUSINESS WIRE)--Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim’s leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leadinBoehringer Ingelheim and Enleofen Ink $1 Billion+ Fibrosis Deal
In the deal, Boehringer acquired worldwide exclusive rights to Enleofen’s preclinical interleukein-11 (IL-11) platform.Scientists Identify New Therapeutic Target for Fatty Liver Disease
Preclinical study highlights a novel therapy for the treatment of fatty liver disease, which affects up to 25% of the global population Inhibiting interleukin 11 (IL11) signalling addresses multiple aspects of non-alcoholic steatohepatitis (NASH), including hepatic inflammation and...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Enleofen Bio
Sign Up For FreeTo access detailed company insights
Enleofen is a biotechnology company focused on developing innovative anti-fibrotic therapies, particularly targeting the IL-11 pathway, which plays a crucial role in fibrogenesis and inflammation in various diseases. The company utilizes a patient-based discovery platform and emphasizes therapeutic development grounded in relevant biology, ensuring... Read More
